Utrecht Holdings

Deal flow originates almost exclusively from the research output of Utrecht University and UMC Utrecht. The firm's team screens approximately 150 invention disclosures annually from faculty and researchers, filing patents on the most promising. Selected projects receive proof-of-concept funding and business development support before being incorporated as independent companies. This proprietary sourcing model — a feed directly from academic labs — is not replicable by outside venture firms.

No. Its mandate is tightly bound to the intellectual property and entrepreneurial activity generated by Utrecht University and its affiliated medical center. The firm does not operate as a generalist venture investor or consider unsolicited pitches from external founders. Its entire portfolio is composed of university spin-outs.

The firm operates at the earliest end of the spectrum: pre-seed and seed, often providing the first external capital a spin-out receives. Instruments include convertible loans, small equity stakes, and venture debt. Finished research products — companies that have advanced through initial development — may also be prepared for divestiture or licensing to established industry partners.

Investment decisions are made by the firm's internal deal team, which includes business developers and investment managers with scientific backgrounds. As a subsidiary of its parent institutions, ultimate governance and major financial commitments likely require approval from university and medical center leadership, aligning the firm's decisions with the broader institutional mission.

It is a private limited company (BV) wholly owned by Utrecht University and UMC Utrecht. While it deploys equity-like instruments, its structure is closer to a university technology-transfer office than an independent, fund-based venture capital firm. It does not raise third-party LP commitments in the traditional sense, operating instead with institutional capital allocated to it by its parent organizations.

Sector focus is a direct reflection of Utrecht University's academic strengths. Core areas include life sciences, medical technology, therapeutics, diagnostics, and regenerative medicine. The firm does not invest in consumer internet, enterprise software, or other sectors without a connection to the university's research output. Its activity is confined to what emerges from its parent institutions' labs.

The firm functions parallel to the university's research grant system rather than operating philanthropic programs itself. Its proof-of-concept funding bridges the gap between academic grants and commercial viability. Any philanthropic structures tied to the university would be managed separately; Utrecht Holdings focuses solely on the commercial translation pathway.